This editorial refers to 'Remote management of heart failure using implantable electronic devices' † , by J.M. Morgan et al., on page 2352.
Implantable devices, including cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICDs), represent a cornerstone of therapy for patients with heart failure (HF). In addition to their established efficacy in improving morbidity and mortality, implantable devices now offer the ability to monitor a range of device and patient parameters continuously. These remote monitoring (RM) platforms are available as standard across several device manufacturers and broadly capture functionalities of the device itself, as well as several proposed surrogates or drivers of HF risk including arrhythmic burden, perturbations of autonomic function, or increases in total body volume. The potential benefits of RM are related to these functionalities and include, for example, optimization of lead parameters to increase device longevity or decrease risk of inappropriate shock, as well as earlier recognition of HF decompensation thus allowing for more timely intervention. While previous observational studies comparing device-based RM with standard clinical care have shown impressive improvements in survival, 1 results from randomized studies have been mixed, with a recent metaanalysis even suggesting a 30% increase in unscheduled office visits. 2 With the proliferation of RM platforms in contemporary devices, coupled with the expanding burden of HF globally, the clinical and financial implications of effectively deploying RM will only intensify. In this issue of the journal, Morgan and colleagues present the results of the REM-HF (Remote Management of Heart Failure Using Implantable Electronic Devices) study, a multicentre, randomized comparison of RM with usual care (UC) in 1650 HF patients with a CRT device and/or an ICD. 3 RM platforms were from a range of manufacturers and included similar but not identical functionalities. The RM intervention included weekly transmission of device data which were reviewed by a study-trained monitor who was then guided to identify general trends in multiple parameters that might indicate HF risk. The clinical response to RM data was protocol driven and generally reflected consensus guidelines when relevant. RM transmission led to a 'clinical action' in 73% of patients in the RM intervention arm. By comparison, in a pragmatic effort to capture the heterogeneity of traditional care, there was no harmonization of follow-up in the UC arm of the study, where bi-annual assessment of device data was allowed for safety purposes. The principle finding of the study was that there was no significant difference between RM and UC for the primary composite endpoint of all-cause mortality or cardiovascular hospitalization, which occurred in 40% of each group over a median follow-up of nearly 3 years. The null findings of the study held over a range of secondary endpoints (including cause-specific mortality and hospitalization) and subgroups (including HF severity, device type, aetiology of cardiomyopathy, and atrial fibrillation). While the REM-HF investigators should be congratulated for presenting this large, pragmatic assessment of RM over such extended follow-up, how exactly do we make sense of these findings in light of the significant mortality reductions identified in both real-world 1, 4 and previous randomized comparisons 5 of RM and UC? To start, we can use the heterogeneity of these RM studies to think instructively about the multiple determinants of RM efficacy ( Figure 1A) . First, the efficacy of RM may depend on both the underlying risk and context of HF. In REM-HF, overall mortality rates in the well-treated study population (>90% beta-blocker, angiotensin-inhibitor use) were similar to previous and favourable observational 4 and randomized RM studies, 5 suggesting that baseline risk differences are not likely to explain these null findings. Nevertheless, eligible patients in REM-HF were clinically stable for 6 months prior to enrolment. Whether device-based RM may provide greater efficacy in transient 'high-risk' contexts (e.g. in the 90-day window after HF hospitalization) remains untested. RM may in fact play an important role in risk stratification itself and thus serve as an inclusion criterion for future RM trials ( Figure 1B) . In addition, the potential benefits of RM may differ in other HF settings such as HF with preserved ejection fraction, where Secondly, RM is only as good as the information provided. More specifically, the effectiveness of RM depends on both the specificity of the alerts for HF risk as well as the lead time to HF decompensation. In general, single-parameter RM strategies have shown less accuracy than multiparameter approaches, 5, 6 although the components of previously tested multiparameter strategies have been heterogeneous. In REM-HF, study monitors were given protocol-based guidance to examine 'trends' across several measures (e.g. decreased heart rate variability, decreasing intrathoracic impedance). How these 'trends' were interpreted by study staff and the accuracy of this particular 'composite' approach remains uncertain. Moreover, study investigators in REM-HF were guided to contact the patient to corroborate evidence of decompensation by symptoms or trends in body weight. Given that these parameters (i.e. symptoms, changes in body weight) reflect relatively 'late' changes in the cascade of HF decompensation, it is possible that the RM strategy in REM-HF may not have provided sufficient lead time to see benefit. Looking ahead, the analysis of trends across multiple device measures is not practical and, in this setting, device-centric algorithms may prove helpful. Indeed, a recent device-based integrative HF index showed >70% sensitivity for HF decompensation with nearly 30-day lead time. 7 If validated, titration of therapies based on integrative measures and independent of symptoms (e.g. akin to the robust approach used with pulmonary artery sensor trials) may prove superior to the 'reactionary' paradigm in contemporary RM. Thirdly, the frequency of RM transmission matters, 2 with weekly RM transmission >75% of the time associated with improved survival in observational studies. 4 In REM-HF, high-frequency transmission (>75% of the weeks) was prevalent in only 60% of participants and the relationship between RM adherence and outcomes would have been of interest. Practically, automated and frequent transmission of multiparameter data may lead to information overload and burnout for any HF care team. In this context, constructing simplified, integrative risk indices that can be efficiently communicated will be key. Fourthly, who receives, interprets, and communicates RM-based decisions may influence its efficacy. Care systems which allow for efficient and empowered communication between RM monitors, specialty physicians who understand the nuances of a given patient's history, and the patient would probably show the greatest benefit with RM technology. In the future, RM-based alerts may allow for patient-driven therapy changes (e.g. additional diuretic dose) or automated drug delivery (e.g. similar to 'insulin pumps' in diabetes), both of which would considerably reduce the time to intervention. Finally, it is worth considering how we define success with RM therapy. In light of the prevalent observational data, the REM-HF investigators sensibly selected a composite endpoint inclusive of overall mortality. However, given the functionalities of several components of RM (e.g. atrial arrhythmia burden, discrimination algorithms reducing risk of inappropriate shocks), it is not surprising that several recent randomized studies have also highlighted non-fatal benefits of RM, including decreased inappropriate shocks 8 and decreased healthcare utilization (e.g. unscheduled office visits).
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Future cost-effective analysis and assessment of other non-fatal endpoints from the REM-HF investigators will be of interest.
In closing, the REM-HF study highlights the limitations of a 'one-size fits all' approach for RM in clinically stable HF patients with a reduced ejection fraction. Looking ahead in an era of integrated and valuebased care, RM remains a promising tool which has the potential to improve both the quality and the efficiency of our care. Opportunity awaits! Conflict of interest: none declared.
